Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3

IF 2.5 4区 医学 Q3 CHEMISTRY, MEDICINAL Bioorganic & Medicinal Chemistry Letters Pub Date : 2024-08-31 DOI:10.1016/j.bmcl.2024.129945
Bowen Yang , Yanhong Cen , Fangfang Li , Yikui Li , Bichun Chen , Jiwei Zheng , Zhongliang Tang , Qiang Gao , Lijing Fang , Fan Pan
{"title":"Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3","authors":"Bowen Yang ,&nbsp;Yanhong Cen ,&nbsp;Fangfang Li ,&nbsp;Yikui Li ,&nbsp;Bichun Chen ,&nbsp;Jiwei Zheng ,&nbsp;Zhongliang Tang ,&nbsp;Qiang Gao ,&nbsp;Lijing Fang ,&nbsp;Fan Pan","doi":"10.1016/j.bmcl.2024.129945","DOIUrl":null,"url":null,"abstract":"<div><p>Regulatory T (Treg) cells play a central role in immune homeostasis. Forkhead box <em>P</em>3 (Foxp3), a hallmark molecule in Treg cells, is a vital transcription factor for their development and function. Studies have shown that degradation of the Foxp3 could provide therapeutic benefits in achieving effective anti-tumor immunity. In this study, we designed three PROTAC molecules, P60-L1-VHL, P60-L2-VHL, and P60-L3-VHL, based on a 15-mer peptide inhibitor of Foxp3 (P60), and explored their potential in regulating Foxp3 expression and function. Our data show that, among these molecules, P60-L3-VHL can inhibit the expression and nuclear localization of Foxp3 in HEK 293 T and HeLa cells, respectively. Meanwhile, use of proteasome inhibitor in P60-L3-VHL treated cells revealed an increased Foxp3 expression, indicating that P60-L3-VHL mediates the inhibition of Foxp3 through its degradation in the proteasome pathway. We further substantiate that P60-L3-VHL reduces the differentiation and Foxp3 expression in the in-vitro activated Treg cells. Overall, our findings suggest that P60-L3-VHL inhibits the differentiation of Treg cells by degrading the Foxp3, which may have potential implications in cancer immunotherapy.</p></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"112 ","pages":"Article 129945"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X24003470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Regulatory T (Treg) cells play a central role in immune homeostasis. Forkhead box P3 (Foxp3), a hallmark molecule in Treg cells, is a vital transcription factor for their development and function. Studies have shown that degradation of the Foxp3 could provide therapeutic benefits in achieving effective anti-tumor immunity. In this study, we designed three PROTAC molecules, P60-L1-VHL, P60-L2-VHL, and P60-L3-VHL, based on a 15-mer peptide inhibitor of Foxp3 (P60), and explored their potential in regulating Foxp3 expression and function. Our data show that, among these molecules, P60-L3-VHL can inhibit the expression and nuclear localization of Foxp3 in HEK 293 T and HeLa cells, respectively. Meanwhile, use of proteasome inhibitor in P60-L3-VHL treated cells revealed an increased Foxp3 expression, indicating that P60-L3-VHL mediates the inhibition of Foxp3 through its degradation in the proteasome pathway. We further substantiate that P60-L3-VHL reduces the differentiation and Foxp3 expression in the in-vitro activated Treg cells. Overall, our findings suggest that P60-L3-VHL inhibits the differentiation of Treg cells by degrading the Foxp3, which may have potential implications in cancer immunotherapy.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
发现蛋白水解靶向嵌合体(PROTAC)可作为 FOXP3 的有效调节剂。
调节性 T 细胞(Tregs)在免疫平衡中发挥着核心作用。叉头框 P3(Foxp3)是 Tregs 的标志性分子,是其发育和功能的重要转录因子,降解 Foxp3 可为实现有效的抗肿瘤免疫提供治疗益处。在这项研究中,我们以 Foxp3 的 15-mer肽抑制剂(P60)为基础设计了三种 PROTAC 分子,即 P60-L1-VHL、P60-L2-VHL 和 P60-L3-VHL,并探索了它们在调控 Foxp3 表达和功能方面的潜力。我们的数据显示,在这些分子中,P60-L3-VHL 可分别抑制 Foxp3 在 HEK 293 T 细胞和 HeLa 细胞中的表达和核定位。同时,在使用蛋白酶体抑制剂处理 P60-L3-VHL 的细胞时,发现 Foxp3 的表达增加了,这表明 P60-L3-VHL 通过蛋白酶体途径降解 Foxp3 来介导对 Foxp3 的抑制。我们进一步证实,P60-L3-VHL 可减少体外激活的 Tregs 的分化和 Foxp3 的表达。总之,我们的研究结果表明,P60-L3-VHL 可通过降解 Foxp3 来抑制 Tregs 的分化,它在癌症免疫疗法中可能具有潜在的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
3.70%
发文量
463
审稿时长
27 days
期刊介绍: Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.
期刊最新文献
Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7. Synthesis and Structure-Activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency. Design, synthesis and bioactivity evaluation of cinnamic acid derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury. Switching off cancer - An overview of G-quadruplex and i-motif functional role in oncogene expression. Synthesis and evaluation of anti-Giardia activity of oseltamivir analogs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1